A 7-year-old boy with ADHD presents with inattention, hyperactivity, and impulsivity affecting school performance. He has no cardiac history, normal blood pressure, and no contraindications to stimulant therapy. What is the drug of choice for first-line pharmacological management?

Explanation

## First-Line Pharmacotherapy for ADHD in Children **Key Point:** Methylphenidate is the gold-standard first-line stimulant for ADHD in children with no cardiac contraindications. It is the most extensively studied and has the strongest evidence base for efficacy and safety in pediatric populations. ### Mechanism of Action Methylphenidate is a sympathomimetic amine that blocks the reuptake of dopamine and norepinephrine in the prefrontal cortex, enhancing executive function, attention, and impulse control. ### Dosing and Formulations - **Immediate-release:** 5–20 mg once or twice daily; onset 30–60 minutes - **Extended-release (ER/XR):** 18–54 mg once daily; preferred for school-day coverage - Titration: Start low (5 mg), increase by 5 mg every 5–7 days based on response and tolerability ### Efficacy and Safety Profile | Feature | Methylphenidate | Atomoxetine | Guanfacine | Bupropion | |---------|-----------------|-------------|-----------|----------| | **Onset** | 30–60 min (IR) | 2–4 weeks | 1–2 weeks | 2–4 weeks | | **Class** | Stimulant | Non-stimulant | α₂-agonist | Antidepressant | | **First-line** | Yes | No (2nd-line) | No (adjunct) | No (2nd-line) | | **Abuse potential** | Moderate | None | None | None | | **BP/HR effect** | ↑ (mild) | Minimal | ↓ (desired) | Minimal | **High-Yield:** Methylphenidate is preferred in children because it has the longest track record, fastest onset, and most predictable dose–response relationship. ### Monitoring Requirements - Baseline: Height, weight, blood pressure, heart rate, cardiac history - During treatment: BP and HR at each visit; growth monitoring every 3–6 months - Appetite and sleep assessment - No routine ECG needed unless cardiac risk factors present **Clinical Pearl:** Extended-release formulations improve compliance and provide continuous coverage through the school day, reducing the need for mid-day dosing. **Warning:** Do NOT use methylphenidate in children with uncontrolled hypertension, cardiac arrhythmias, or severe structural heart disease. Screen for family history of sudden cardiac death. ### Why Other Options Are Not First-Line - **Atomoxetine:** Non-stimulant, slower onset (2–4 weeks), reserved for stimulant-intolerant or abuse-risk patients - **Guanfacine:** α₂-agonist, used as adjunct or monotherapy in comorbid aggression/tics; not first-line monotherapy - **Bupropion:** Antidepressant, used for ADHD with comorbid depression; not first-line for uncomplicated ADHD [cite:Harrison 21e Ch 387]